Why the study?
Anticoagulation in atrial fibrillation often relies on fixed dosing with infrequent adjustments and fails to incorporate patient preferences regarding risks of stroke, bleeding, and death.
Does the Adele Bayesian machine learning model improve predictive accuracy for 3-year clinical events in patients with atrial fibrillation compared to standard Kaplan-Meier estimators?
Does the Adele Bayesian machine learning model improve predictive accuracy for 3-year clinical events in patients with atrial fibrillation compared to standard Kaplan-Meier estimators?
A novel Bayesian machine learning model integrating pharmacokinetic and clinical data significantly improves dynamic risk prediction for clinical events in atrial fibrillation compared to traditional static models, enabling personalized, preference-weighted edoxaban dosing.
Answers are grounded in this paper and cite their sources.
Personalized Bayesian dosing model for edoxaban in AF; hypothesis-generating and requires prospective validation before practice change.
BACKGROUND: Anticoagulation in atrial fibrillation often relies on a fixed dose and infrequent dose adjustment and does not incorporate patient preferences for risks of stroke, bleeding, and death. OBJECTIVES: We developed a Bayesian machine learning model (Adele) to guide individualized long-term dosing accounting for patient preferences. METHODS: Adele is a Bayesian competing-risk, multistate hazard model trained on 5,380 edoxaban-treated patients with atrial fibrillation with pharmacokinetic (PK) data from the ENGAGE AF-TIMI 48 (Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-TIMI 48) trial. Patient PK and baseline data were used to estimate personalized continual risk prediction. The concordance index compared predictive accuracy of Adele with standard Kaplan-Meier estimators. Positive concordance index values (%) indicate better predictive accuracy for Adele. In 2 patient examples, we demonstrate Adele's ability to predict 3-year event frequencies at randomization and following intercurrent events identifying optimal dosing across three edoxaban doses (60mg, 30mg, 15mg) based on hypothetical outcome preferences. RESULTS: Adele outperformed Kaplan-Meier estimators, improving 3-year prediction for cardiovascular death by +12.1%, disability by +11.8%, major gastrointestinal bleeding by +13.7%, and ischemic stroke (IS) by +3.3%. Adele demonstrated dynamic risk prediction capabilities, with future event probabilities shifting following intracranial hemorrhage or IS. In patient A (80-yr female; 52 kg), preference-weighted event rates were lowest at 15 mg and 30 mg, irrespective of the preference to avoid cardiovascular death, major bleeding, or disability. In patient B (72-yr male; 80 kg), preference-weighted event rates were lowest at 60 mg, irrespective of the preference to avoid death or IS/intracranial hemorrhage, and instead lowest at 15 mg for disability avoidance. CONCLUSIONS: Adele represents a state-of-the-art Bayesian framework, using clinical factors and PK data, to enable longitudinally adaptive, patient-centric, preference-weighted predictions.
No takes yet. Share an insight, caveat, or question.
Gibson et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: